マラリア(Malaria):治療薬開発パイプライン動向(2016年下半期版)

◆英語タイトル:Malaria - Pipeline Review, H2 2016
◆商品コード:DATA70209206
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2016年11月16日
◆ページ数:413
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥224,000見積依頼/購入/質問フォーム
Site LicenseUSD4,000 ⇒換算¥448,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD6,000 ⇒換算¥672,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界におけるマラリア(Malaria)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・マラリア(Malaria)の概要
・マラリア(Malaria)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・マラリア(Malaria)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・マラリア(Malaria)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・マラリア(Malaria)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Malaria – Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Malaria – Pipeline Review, H2 2016, provides an overview of the Malaria (Infectious Disease) pipeline landscape.

Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. Treatment includes anti-malarial medicines and healthy lifestyle.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Malaria – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Malaria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malaria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Malaria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 12, 7, 62 and 29 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 14, 46 and 41 molecules, respectively.Malaria.

Malaria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Malaria (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Malaria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Malaria (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Malaria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Malaria (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Malaria (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Malaria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
Introduction 6
Malaria Overview 7
Therapeutics Development 8
Malaria – Therapeutics under Development by Companies 10
Malaria – Therapeutics under Investigation by Universities/Institutes 15
Malaria – Pipeline Products Glance 19
Malaria – Products under Development by Companies 22
Malaria – Products under Investigation by Universities/Institutes 29
Malaria – Companies Involved in Therapeutics Development 36
Malaria – Therapeutics Assessment 99
Drug Profiles 111
Malaria – Dormant Projects 362
Malaria – Discontinued Products 375
Malaria – Product Development Milestones 377
Appendix 390

List of Tables
Number of Products under Development for Malaria, H2 2016 30
Number of Products under Development for Malaria - Comparative Analysis, H2 2016 31
Number of Products under Development by Companies, H2 2016 32
Number of Products under Development by Companies, H2 2016 (Contd..1) 33
Number of Products under Development by Companies, H2 2016 (Contd..2) 34
Number of Products under Development by Companies, H2 2016 (Contd..3) 35
Number of Products under Development by Companies, H2 2016 (Contd..4) 36
Number of Products under Investigation by Universities/Institutes, H2 2016 37
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 38
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 39
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 40
Comparative Analysis by Late Stage Development, H2 2016 41
Comparative Analysis by Clinical Stage Development, H2 2016 42
Comparative Analysis by Early Stage Development, H2 2016 43
Products under Development by Companies, H2 2016 44
Products under Development by Companies, H2 2016 (Contd..1) 45
Products under Development by Companies, H2 2016 (Contd..2) 46
Products under Development by Companies, H2 2016 (Contd..3) 47
Products under Development by Companies, H2 2016 (Contd..4) 48
Products under Development by Companies, H2 2016 (Contd..5) 49
Products under Development by Companies, H2 2016 (Contd..6) 50
Products under Investigation by Universities/Institutes, H2 2016 51
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 52
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 53
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 54
Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 55
Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 56
Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 57
Malaria - Pipeline by 4SC AG, H2 2016 58
Malaria - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 59
Malaria - Pipeline by Actelion Ltd, H2 2016 60
Malaria - Pipeline by Agilvax Inc, H2 2016 61
Malaria - Pipeline by Akshaya Bio Inc., H2 2016 62
Malaria - Pipeline by Allergy Therapeutics Plc, H2 2016 63
Malaria - Pipeline by Amura Holdings Limited, H2 2016 64
Malaria - Pipeline by Anacor Pharmaceuticals, Inc., H2 2016 65
Malaria - Pipeline by Artificial Cell Technologies, Inc., H2 2016 66
Malaria - Pipeline by AstraZeneca Plc, H2 2016 67
Malaria - Pipeline by Bharat Biotech International Limited, H2 2016 68
Malaria - Pipeline by Callaghan Innovation Research Ltd., H2 2016 69
Malaria - Pipeline by Carna Biosciences, Inc., H2 2016 70
Malaria - Pipeline by CEL-SCI Corporation, H2 2016 71
Malaria - Pipeline by Celgene Corporation, H2 2016 72
Malaria - Pipeline by Cellceutix Corporation, H2 2016 73
Malaria - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 74
Malaria - Pipeline by Cilian AG, H2 2016 75
Malaria - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 76
Malaria - Pipeline by DesignMedix, Inc., H2 2016 77
Malaria - Pipeline by Eisai Co., Ltd., H2 2016 78
Malaria - Pipeline by GenVec, Inc., H2 2016 79
Malaria - Pipeline by Genzyme Corporation, H2 2016 80
Malaria - Pipeline by GlaxoSmithKline Plc, H2 2016 81
Malaria - Pipeline by Hager Biosciences, LLC, H2 2016 82
Malaria - Pipeline by Horizon Pharma Plc, H2 2016 83
Malaria - Pipeline by iBio, Inc., H2 2016 84
Malaria - Pipeline by Imaxio SA, H2 2016 85
Malaria - Pipeline by Immtech Pharmaceuticals, Inc., H2 2016 86
Malaria - Pipeline by Immunovaccine Inc, H2 2016 87
Malaria - Pipeline by IPCA Laboratories Limited, H2 2016 88
Malaria - Pipeline by IRBM Science Park SpA, H2 2016 89
Malaria - Pipeline by Jenrin Discovery, Inc., H2 2016 90
Malaria - Pipeline by Jomaa Pharma GmbH, H2 2016 91
Malaria - Pipeline by Kancera AB, H2 2016 92
Malaria - Pipeline by Kymab Limited, H2 2016 93
Malaria - Pipeline by Lipocure Ltd., H2 2016 94
Malaria - Pipeline by Lipotek Pty Ltd., H2 2016 95
Malaria - Pipeline by LondonPharma Ltd, H2 2016 96
Malaria - Pipeline by Merck & Co., Inc., H2 2016 97
Malaria - Pipeline by Merck KGaA, H2 2016 98
Malaria - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2016 99
Malaria - Pipeline by Microbiotix, Inc., H2 2016 100
Malaria - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 101
Malaria - Pipeline by Mucosis B.V., H2 2016 102
Malaria - Pipeline by Mymetics Corporation, H2 2016 103
Malaria - Pipeline by Novartis AG, H2 2016 104
Malaria - Pipeline by PaxVax, Inc., H2 2016 105
Malaria - Pipeline by Pfenex Inc., H2 2016 106
Malaria - Pipeline by Pfizer Inc., H2 2016 107
Malaria - Pipeline by Protein Potential, LLC, H2 2016 108
Malaria - Pipeline by Rodos BioTarget GmbH, H2 2016 109
Malaria - Pipeline by Sanaria Inc., H2 2016 110
Malaria - Pipeline by Sanofi, H2 2016 111
Malaria - Pipeline by SBI Pharmaceuticals Co., Ltd., H2 2016 112
Malaria - Pipeline by Selecta Biosciences, Inc., H2 2016 113
Malaria - Pipeline by Sigma-Tau S.p.A., H2 2016 114
Malaria - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 115
Malaria - Pipeline by Telormedix SA, H2 2016 116
Malaria - Pipeline by Tomegavax, Inc., H2 2016 117
Malaria - Pipeline by VLP Biotech, Inc., H2 2016 118
Malaria - Pipeline by VLP Therapeutics, LLC, H2 2016 119
Malaria - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 120
Assessment by Monotherapy Products, H2 2016 121
Assessment by Combination Products, H2 2016 122
Number of Products by Stage and Target, H2 2016 124
Number of Products by Stage and Mechanism of Action, H2 2016 127
Number of Products by Stage and Route of Administration, H2 2016 130
Number of Products by Stage and Molecule Type, H2 2016 132
Malaria - Dormant Projects, H2 2016 384
Malaria - Dormant Projects (Contd..1), H2 2016 385
Malaria - Dormant Projects (Contd..2), H2 2016 386
Malaria - Dormant Projects (Contd..3), H2 2016 387
Malaria - Dormant Projects (Contd..4), H2 2016 388
Malaria - Dormant Projects (Contd..5), H2 2016 389
Malaria - Dormant Projects (Contd..6), H2 2016 390
Malaria - Dormant Projects (Contd..7), H2 2016 391
Malaria - Dormant Projects (Contd..8), H2 2016 392
Malaria - Dormant Projects (Contd..9), H2 2016 393
Malaria - Dormant Projects (Contd..10), H2 2016 394
Malaria - Dormant Projects (Contd..11), H2 2016 395
Malaria - Dormant Projects (Contd..12), H2 2016 396
Malaria - Discontinued Products, H2 2016 397
Malaria - Discontinued Products (Contd..1), H2 2016 398

List of Figures
Number of Products under Development for Malaria, H2 2016 30
Number of Products under Development for Malaria - Comparative Analysis, H2 2016 31
Number of Products under Development by Companies, H2 2016 32
Number of Products under Investigation by Universities/Institutes, H2 2016 37
Comparative Analysis by Late Stage Development, H2 2016 41
Comparative Analysis by Clinical Stage Development, H2 2016 42
Comparative Analysis by Early Stage Products, H2 2016 43
Assessment by Monotherapy Products, H2 2016 121
Assessment by Combination Products, H2 2016 122
Number of Products by Top 10 Targets, H2 2016 123
Number of Products by Stage and Top 10 Targets, H2 2016 123
Number of Products by Top 10 Mechanism of Actions, H2 2016 126
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 126
Number of Products by Routes of Administration, H2 2016 129
Number of Products by Stage and Routes of Administration, H2 2016 129
Number of Products by Top 10 Molecule Types, H2 2016 131
Number of Products by Stage and Top 10 Molecule Types, H2 2016 131

【レポートのキーワード】

マラリア(Malaria)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[マラリア(Malaria):治療薬開発パイプライン動向(2016年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆